Vertex Pharmaceuticals (VRTX) Convertible Debt (2010 - 2013)
Vertex Pharmaceuticals (VRTX) posted quarterly Convertible Debt of $400.0 million for Q1 2013, little changed year-over-year from $400.0 million in Q1 2012, and little changed quarter-over-quarter from $400.0 million in Q4 2012.
Vertex Pharmaceuticals (VRTX) Convertible Debt (2010 - 2013) Analysis & Trends
Vertex Pharmaceuticals' Convertible Debt history runs 4 years deep, the most recent figure standing at $400.0 million for Q1 2013.
- In Q1 2013, Convertible Debt changed 0.0% year-over-year to $400.0 million; the TTM figure through Mar 2013 stood at $400.0 million (changed 0.0% YoY), while the FY2012 annual figure was $400.0 million, changed 0.0% from the prior year.
- Convertible Debt for Q1 2013 stood at $400.0 million, roughly flat from $400.0 million in the prior quarter.
- The five-year high for Convertible Debt was $400.0 million in Q3 2010, with the low at $32.1 million in Q1 2010.
- The 4-year median for Convertible Debt is $400.0 million (2010), against an average of $366.6 million.
- Peak annual rise in Convertible Debt reached 1146.11% in 2011, while the deepest fall reached 0.0% in 2011.
- Vertex Pharmaceuticals' Convertible Debt stood at $400.0 million in 2010, then changed by 0.0% to $400.0 million in 2011, then changed by 0.0% to $400.0 million in 2012, then changed by 0.0% to $400.0 million in 2013.
- Business Quant data shows VRTX's Convertible Debt at $400.0 million in Q1 2013, $400.0 million in Q4 2012, and $400.0 million in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 400.00 Mn |
| Dec 31, 2012 | 400.00 Mn |
| Sep 30, 2012 | 400.00 Mn |
| Jun 30, 2012 | 400.00 Mn |
| Mar 31, 2012 | 400.00 Mn |
| Dec 31, 2011 | 400.00 Mn |
| Sep 30, 2011 | 400.00 Mn |
| Mar 31, 2011 | 400.00 Mn |
| Dec 31, 2010 | 400.00 Mn |
| Sep 30, 2010 | 400.00 Mn |
| Mar 31, 2010 | 32.10 Mn |